A Long-Term Extension Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Patients With Graves' Disease
Latest Information Update: 03 Mar 2026
At a glance
- Drugs Imeroprubart (Primary)
- Indications Graves' disease
- Focus Therapeutic Use
- Sponsors Immunovant Sciences
Most Recent Events
- 27 Feb 2026 Status changed from not yet recruiting to recruiting.
- 23 Dec 2025 New trial record